vs
Side-by-side financial comparison of CASTLE BIOSCIENCES INC (CSTL) and SunPower Inc. (SPWR). Click either name above to swap in a different company.
CASTLE BIOSCIENCES INC is the larger business by last-quarter revenue ($87.0M vs $79.7M, roughly 1.1× SunPower Inc.). On growth, CASTLE BIOSCIENCES INC posted the faster year-over-year revenue change (0.8% vs -10.1%). Over the past eight quarters, SunPower Inc.'s revenue compounded faster (118.7% CAGR vs 9.2%).
Castle Biosciences Inc. is a commercial-stage diagnostic firm that develops and markets proprietary, clinically actionable tests for dermatological conditions such as melanoma and other skin cancers, plus rare diseases. It operates mainly in the U.S. healthcare market, focusing on segments with high unmet need for more accurate diagnostics to guide treatment choices.
SunPower Corporation is an American provider of photovoltaic solar energy generation systems and battery energy storage products, primarily for residential customers. The company, headquartered in San Jose, California, was founded in 1985 by Richard Swanson, an electrical engineering professor from Stanford University. Cypress Semiconductor bought a majority interest in the company in 2002, growing it quickly until SunPower went public in 2005. TotalEnergies, a French energy and oil company p...
CSTL vs SPWR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $87.0M | $79.7M |
| Net Profit | — | $-14.2M |
| Gross Margin | 79.0% | 35.5% |
| Operating Margin | -4.4% | -27.4% |
| Net Margin | — | -17.8% |
| Revenue YoY | 0.8% | -10.1% |
| Net Profit YoY | — | -130.1% |
| EPS (diluted) | $-0.06 | $-0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $87.0M | $79.7M | ||
| Q3 25 | $83.0M | $22.0M | ||
| Q2 25 | $86.2M | $67.5M | ||
| Q1 25 | $88.0M | $82.7M | ||
| Q4 24 | $86.3M | $88.7M | ||
| Q3 24 | $85.8M | — | ||
| Q2 24 | $87.0M | — | ||
| Q1 24 | $73.0M | — |
| Q4 25 | — | $-14.2M | ||
| Q3 25 | $-501.0K | $-16.9M | ||
| Q2 25 | $4.5M | $-22.4M | ||
| Q1 25 | $-25.8M | $8.1M | ||
| Q4 24 | — | $47.0M | ||
| Q3 24 | $2.3M | — | ||
| Q2 24 | $8.9M | — | ||
| Q1 24 | $-2.5M | — |
| Q4 25 | 79.0% | 35.5% | ||
| Q3 25 | 77.5% | — | ||
| Q2 25 | 79.5% | 42.6% | ||
| Q1 25 | 81.4% | 48.5% | ||
| Q4 24 | 81.3% | 46.5% | ||
| Q3 24 | 81.8% | — | ||
| Q2 24 | 83.3% | — | ||
| Q1 24 | 81.0% | — |
| Q4 25 | -4.4% | -27.4% | ||
| Q3 25 | -8.2% | -15.7% | ||
| Q2 25 | -4.9% | -4.0% | ||
| Q1 25 | -31.7% | 1.3% | ||
| Q4 24 | 4.7% | -24.2% | ||
| Q3 24 | 5.9% | — | ||
| Q2 24 | 5.8% | — | ||
| Q1 24 | -7.5% | — |
| Q4 25 | — | -17.8% | ||
| Q3 25 | -0.6% | -76.9% | ||
| Q2 25 | 5.2% | -33.2% | ||
| Q1 25 | -29.4% | 9.8% | ||
| Q4 24 | — | 53.0% | ||
| Q3 24 | 2.6% | — | ||
| Q2 24 | 10.3% | — | ||
| Q1 24 | -3.5% | — |
| Q4 25 | $-0.06 | $-0.05 | ||
| Q3 25 | $-0.02 | $-0.19 | ||
| Q2 25 | $0.15 | $-0.28 | ||
| Q1 25 | $-0.90 | $0.00 | ||
| Q4 24 | $0.32 | $0.27 | ||
| Q3 24 | $0.08 | — | ||
| Q2 24 | $0.31 | — | ||
| Q1 24 | $-0.09 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $299.5M | $9.6M |
| Total DebtLower is stronger | $10.1M | $164.8M |
| Stockholders' EquityBook value | $470.9M | $-90.1M |
| Total Assets | $578.6M | $241.2M |
| Debt / EquityLower = less leverage | 0.02× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $299.5M | $9.6M | ||
| Q3 25 | $287.5M | $5.1M | ||
| Q2 25 | $275.9M | $11.1M | ||
| Q1 25 | $275.2M | $10.6M | ||
| Q4 24 | $293.1M | $13.4M | ||
| Q3 24 | $95.0M | — | ||
| Q2 24 | $85.6M | — | ||
| Q1 24 | $82.9M | — |
| Q4 25 | $10.1M | $164.8M | ||
| Q3 25 | $10.0M | $204.3M | ||
| Q2 25 | $10.0M | $152.9M | ||
| Q1 25 | $10.0M | — | ||
| Q4 24 | $10.0M | $147.3M | ||
| Q3 24 | $10.0M | — | ||
| Q2 24 | $10.0M | — | ||
| Q1 24 | $10.0M | — |
| Q4 25 | $470.9M | $-90.1M | ||
| Q3 25 | $467.0M | $-112.3M | ||
| Q2 25 | $455.4M | $-107.2M | ||
| Q1 25 | $440.3M | $-89.0M | ||
| Q4 24 | $455.8M | $-97.5M | ||
| Q3 24 | $441.1M | — | ||
| Q2 24 | $423.9M | — | ||
| Q1 24 | $402.5M | — |
| Q4 25 | $578.6M | $241.2M | ||
| Q3 25 | $562.8M | $208.3M | ||
| Q2 25 | $544.7M | $163.1M | ||
| Q1 25 | $501.7M | $147.8M | ||
| Q4 24 | $531.2M | $144.5M | ||
| Q3 24 | $514.6M | — | ||
| Q2 24 | $487.3M | — | ||
| Q1 24 | $458.5M | — |
| Q4 25 | 0.02× | — | ||
| Q3 25 | 0.02× | — | ||
| Q2 25 | 0.02× | — | ||
| Q1 25 | 0.02× | — | ||
| Q4 24 | 0.02× | — | ||
| Q3 24 | 0.02× | — | ||
| Q2 24 | 0.02× | — | ||
| Q1 24 | 0.02× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $26.9M | $-1.9M |
| Free Cash FlowOCF − Capex | $19.7M | — |
| FCF MarginFCF / Revenue | 22.7% | — |
| Capex IntensityCapex / Revenue | 8.3% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $28.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $26.9M | $-1.9M | ||
| Q3 25 | $22.6M | $-6.4M | ||
| Q2 25 | $20.8M | $-4.4M | ||
| Q1 25 | $-6.0M | $-2.6M | ||
| Q4 24 | $24.4M | $-25.6M | ||
| Q3 24 | $23.3M | — | ||
| Q2 24 | $24.0M | — | ||
| Q1 24 | $-6.8M | — |
| Q4 25 | $19.7M | — | ||
| Q3 25 | $7.8M | — | ||
| Q2 25 | $11.6M | — | ||
| Q1 25 | $-10.8M | — | ||
| Q4 24 | $16.8M | — | ||
| Q3 24 | $17.0M | — | ||
| Q2 24 | $18.8M | — | ||
| Q1 24 | $-16.0M | — |
| Q4 25 | 22.7% | — | ||
| Q3 25 | 9.4% | — | ||
| Q2 25 | 13.4% | — | ||
| Q1 25 | -12.2% | — | ||
| Q4 24 | 19.5% | — | ||
| Q3 24 | 19.8% | — | ||
| Q2 24 | 21.6% | — | ||
| Q1 24 | -21.9% | — |
| Q4 25 | 8.3% | — | ||
| Q3 25 | 17.9% | — | ||
| Q2 25 | 10.7% | — | ||
| Q1 25 | 5.4% | — | ||
| Q4 24 | 8.8% | — | ||
| Q3 24 | 7.4% | — | ||
| Q2 24 | 6.0% | — | ||
| Q1 24 | 12.5% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 4.60× | — | ||
| Q1 25 | — | -0.32× | ||
| Q4 24 | — | -0.54× | ||
| Q3 24 | 10.29× | — | ||
| Q2 24 | 2.69× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CSTL
| Dermatologic | $48.6M | 56% |
| Non Dermatologic | $38.4M | 44% |
SPWR
| Residential Solar Installation | $46.9M | 59% |
| New Homes Business | $22.7M | 29% |
| Other | $10.1M | 13% |
